Edition:
India

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

14.79USD
1:30am IST
Change (% chg)

$0.10 (+0.68%)
Prev Close
$14.69
Open
$14.60
Day's High
$14.79
Day's Low
$14.60
Volume
264
Avg. Vol
3,778
52-wk High
$20.35
52-wk Low
$12.32

Latest Key Developments (Source: Significant Developments)

Reg-Zealand Pharma Achieves Milestone In First Phase 3 Trial
Friday, 8 Jun 2018 

June 8 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ACHIEVES MILESTONE IN FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.RESULTS OF FIRST COMPLETED PHASE 3 TRIALS CONFIRM DASIGLUCAGON'S SAFETY AND EFFICACY PROFILE IN PATIENTS WITH TYPE 1 DIABETES.IN ADDITION TO THIS TRIAL, A SECOND AND PIVOTAL PHASE 3 EFFICACY TRIAL WAS INITIATED LATE 2017 AND LAST PATIENT VISIT OCCURRED IN MAY 2018.FINAL RESULTS ARE EXPECTED IN Q3 2018..  Full Article

Zealand Pharma To Present New Clinical Phase 2 Results On Glepaglutide
Thursday, 31 May 2018 

May 31 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA TO PRESENT NEW CLINICAL PHASE 2 RESULTS ON GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME AT THE DDW CONFERENCE IN THE U.S..RESULTS DEMONSTRATES GLEPAGLUTIDE'S EFFECTS ON INTESTINAL TRANSIT TIME, MORPHOLOGY AND ENERGY ABSORPTION.REMAINS ON TRACK TO INITIATE PIVOTAL PHASE 3 TRIAL, WITH WEEKLY AND TWICE-WEEKLY DOSING OF GLEPAGLUTIDE, IN H2 2018.SUPPORTS PRIMARY RESULTS OF TRIAL, WHICH DEMONSTRATED REDUCTIONS IN DIARRHEA/FECAL OUTPUT AND INCREASES IN INTESTINAL WET WEIGHT ABSORPTION.  Full Article

Zealand Pharma: Phase 3 Trial With Dasiglucagon Successfully Met Primary Objective
Monday, 28 May 2018 

May 28 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA REPORTS COMPLETION OF THE SECOND AND PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA.KEY RESULTS NOW EXPECTED IN Q3 2018.PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA TO HAVE SUCCESSFULLY MET PRIMARY OBJECTIVE IN Q1.  Full Article

Zealand Pharma Q1 Net loss at DKK 91.4 mln
Wednesday, 16 May 2018 

May 16 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST QUARTER OF 2018.Q1 REVENUE DKK 10.8 MILLION VERSUS DKK 77.6 MILLION YEAR AGO.Q1 NET LOSS DKK 91.4 MILLION VERSUS LOSS DKK 26.3 MILLION YEAR AGO.THERE WAS NO MILESTONE REVENUE IN Q1 2018.MAINTAINS ITS FINANCIAL GUIDANCE FOR FULL-YEAR 2018.  Full Article

Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - ZEALAND PHARMA A/S ::ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC..POTENTIAL FUTURE INVESTMENTS OF UP TO USD 3.5 MILLION ARE LINKED TO CLINICAL DEVELOPMENT MILESTONES.COLLABORATES WITH BETA BIONICS TO ADVANCE DEVELOPMENT OF ITS DASIGLUCAGON IN ILET(TM).  Full Article

Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.SAYS RESULTS FROM PHASE 3 TRIAL EXPECTED IN H2 2018​.  Full Article

Zealand Pharma Q3 operating loss at DKK 38.2 mln ​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - ZEALAND PHARMA A/S ::‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​.‍REVISED FINANCIAL GUIDANCE FOR 2017​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED (DKK 390-410 MILLION).​.Q3 REVENUE DKK 40.1‍​ MILLION VERSUS DKK 39.6 MILLION YEAR AGO.2017 ‍OPERATING LOSS BEFORE ROYALTY INCOME/EXPENSES HAS BEEN REDUCED FROM DKK 290-310 MILLION TO DKK 275-285 MILLION​.‍FOR 2017, ZEALAND MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI​.Q3 OPERATING LOSS DKK 38.2 ‍​ MILLION VERSUS LOSS DKK 21.2 MILLION YEAR AGO.  Full Article

Zealand reports royalty revenue Of DKK 10.3 mln for Q3
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - ZEALAND PHARMA A/S :REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017.‍ZEALAND REPORTS ROYALTY REVENUE OF DKK 10.3 MILLION/USD 1.6 MILLION FOR Q3 2017​.  Full Article

Zealand Pharma granted orphan drug designation by FDA
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - ZEALAND PHARMA A/S ::REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME.‍FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT HAS GRANTED AN ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE​.  Full Article

Zealand Pharma Q2 operating loss widening to DKK 88.0 million
Thursday, 25 Aug 2016 

Zealand Pharma A/S : Q2 operating loss 88.0 million Danish crowns ($13.33 million) versus loss 64.6 million crowns year ago . Q2 revenue 7.9 million crowns versus 7.3 million crowns year ago . Financial guidance for 2016 unchanged .Maintains its revenue guidance for full-year.  Full Article

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018